Vitamin B12, Neurodevelopment and Growth in Nepal (BeLive)

• ClinicalTrials.gov Identifier: NCT02272842
• Recruitment Status: Active, not recruiting
• First Posted: October 23, 2014
• Results First Posted: May 25, 2021
• Last Update Posted: May 25, 2021
• Sponsor: Centre For International Health
• Collaborators: Tribhuvan University, Nepal; NORCE Norwegian Research Centre AS
• Information provided by (Responsible Party): Centre For International Health

Study Description

Brief Summary:

Rationale: Globally, vitamin B12 deficiency is one of the most common micronutrient deficiencies. The only relevant source of Vitamin B12 is animal-source foods. Vitamin B12 is crucial for normal cell division and is necessary for brain growth as well as for the maintenance of its normal function. Deficiency is also associated with impaired growth. In a previous study, we demonstrated that vitamin B12 administration over a period of six months enhanced growth, and scores on a neuro-developmental test in young Indian children. However, the overall effect was small and, for the developmental scores significant only in those that were malnourished at the start of the study.

Our findings need to be verified in trials targeting younger, malnourished children and with longer supplementation time.

Hypothesis: This proposed study will test three hypotheses; to measure to what extent 2 recommended daily allowances (RDA) of vitamin B12 administration for one year to stunted children improves; 1) growth, 2) neurodevelopment, and 3) hemoglobin concentration.

Study design: Randomized placebo-controlled trial. Half of the children will receive a paste containing vitamin B12, the other half the same paste but without vitamin B12.

Study participants and site: 600 malnourished infants in Bhaktapur municipality in Nepal. In this population we have demonstrated that vitamin B12 deficiency and poor growth is common in early childhood.

Intervention: Daily administration of a paste containing vitamin B12 or placebo for 12 months

Data: The main outcomes of this study are scores on developmental assessments tools and growth measured every month for 12 months.

Condition or disease	Intervention/treatment	Phase
Development; Vitamin Deficiency; Malnutrition	Dietary Supplement: Vitamin B12	Phase 2; Phase 3

Detailed Description:

Scientific basis: Globally, vitamin B12 deficiency is one of the most common micronutrient deficiencies. The only relevant source of vitamin B12 is animal-source foods. Vitamin B12 is crucial for normal cell division and differentiation and is necessary for the development and initial myelination of the central nervous system as well as for the maintenance of its normal function. Deficiency is also associated with impaired infant and child growth.

In a previous clinical trial, we demonstrated that vitamin B12 administration over a period of six months enhanced growth and neurodevelopment in young Indian children. The overall effect on growth was significant but small. We saw an effect on both ponderal (weight for age z scores) and linear (height for age z scores) growth. However, the overall effects were driven by the effects in the subgroups of children who were wasted, underweight or stunted at baseline, and no effect in the children who were not malnourished at baseline. This effect modification was significant for all three (stunting, wasting, and underweight) baseline variables. Similarly, the effect of the intervention on neurodevelopmental scores was also strongest in the subgroup of children that were stunted.

We have for the last 15 years undertaken studies on dietary intake and status in women and children in Bhaktapur, Nepal. In this site, vitamin B12 deficiency is very common. The objective of the proposed study is to measure to what extent administration of 2 RDA of vitamin B12 to stunted children from the last half of infancy and for 12 months affect neurodevelopment, growth and hemoglobin concentration.

Hypothesis: Daily supplementation of 2 RDA of vitamin B12 in young Nepali children for 12 months improves neurodevelopment, growth and hemoglobin concentration.

Study design: Individually randomized placebo controlled, double blind trial. Children will be identified in the community and stunted children will be randomized to daily receive a paste containing vitamin B12 or a placebo paste. The paste will be delivered by trained field workers every day and by the caregivers on Saturdays and public holidays.

Study participants and site: 600 stunted children aged 6 to 11 months in Bhaktapur municipality and surrounding areas.

Intervention: Daily administration of a paste containing vitamin B12 or placebo for 12 months.

Comparator: Placebo, identical to the vitamin B12 supplements.

Data: Primary outcomes: (i) neurodevelopmental scores measured by Bayley Scales of Infant and Toddler Development 3rd edition and the Ages and Stages Questionnaire 3rd edition after 6 and 12 months of supplementation (ii) growth measured by change in height for age, weight for age and weight for height z-score from study start to end study and growth velocity z scores during the six first and six last months of supplementation (iii) hemoglobin concentration after 12 months of supplementation. Secondary: (i) cognitive development in children measured approximately 3 and 6 years after enrollment, (ii) linear and ponderal growth measured 2 and 3 years after enrollment, (iii) hemoglobin concentration measured 2 and 3 years after enrollment. All secondary outcomes require additional funding.

Relevance for programs and public health: Improved learning ability and growth in young malnourished children. If the supplementation is effective this will have consequences for dietary recommendation to malnourished children worldwide. In contrast to most other relevant nutritional interventions, vitamin B12 is inexpensive and our body has the ability to store vitamin B12, up to years. Thus, improving the status of this nutrient for a limited time period may have impact on learning and productivity beyond the time of administration and help to lift poor children out of the vicious cycle of poverty and malnutrition.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 600 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Prevention
• Official Title: The Effect of Vitamin B12 Supplementation in Nepali Infants on Growth and Development
• Actual Study Start Date: April 20, 2015
• Actual Primary Completion Date: February 28, 2018
• Estimated Study Completion Date: February 28, 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: Vitamin B12; A paste containing vitamin B12 2µg per 10 mL administered every day. The paste also contains 1 RDA of several other vitamins. The paste is produced by Compact (Norway / India)	Dietary Supplement: Vitamin B12; Vitamin B12 in a multivitamin paste.; Other Name: Cobalamin
Placebo Comparator: Placebo; A paste containing no vitamin administered every day. The paste also contains 1 RDA of several vitamins, but no vitamin B12. The paste is produced by Compact (Norway / India)	Dietary Supplement: Vitamin B12; Vitamin B12 in a multivitamin paste.; Other Name: Cobalamin

Outcome Measures

Primary Outcome Measures :

1. The Bayley Scales of Infant Development Version 3 [ Time Frame: 12 months ]
   Cognitive, Fine Motor, Gross Motor, Receptive language, and Expressive language scaled scores of the Bayley Scales of Infant Development version 3. This scale measures different aspects of neurodevelopment. The mean (SD) scores are usually 100 (15), 95% of the population have scores between 70 and 130 (theoretical max/means 0/200). The higher scores, the better neurodevelopment, the scale is normalized on age.
2. Hemoglobin Concentration [ Time Frame: 12 months ]
   Change in hemoglobin concentration from baseline to end study.

Secondary Outcome Measures :

1. Growth Velocity Over the First Six Months of Supplementation [ Time Frame: 12 months ]
   length and weight growth velocity z scores during supplementation z-scores, growth velocity. theoretical values -10 to 10 The higher the value, the faster the growth.
2. Predictors for Neurodevelopment in Young Nepali Children [ Time Frame: 12 months ]
   Using the collected data, identify morbidity, stimulation, nutrition, socioeconomic related predictors for neurodevelopment.
3. Identify Subgroups of Children Who Benefit From Vitamin B12 Supplementation [ Time Frame: 12 months ]
   Based on selected baseline variables we will identify subgroups who benefit from vitamin B12 supplementation
4. The Effect of Vitamin B12 Supplementation on Markers of Vitamin B Status [ Time Frame: 12 months ]
   We will draw a blood sample at study start and at end study to measure to what extent vitamin status is altered.
5. Neurodevelopment Measured by Other Tools. [ Time Frame: 12 months ]
   We will measure to what extent vitamin B12 supplementation improves neurodevelopment measured by other tools such as the Ages and Stages Questionnaire (version 3) and the NEPSY II test.
6. Immediate Adverse Effects of the Intervention [ Time Frame: 12 months ]
   We will investigate side effects such as pain, nausea, vomiting, regurgitation, allergic reactions and others after each dose of the intervention.
7. Leucocyte Telomere Length [ Time Frame: 12 months ]
   Relative leucocyte telomere length at end of the study period. Estimated by real-time PCR analysis
8. Sleep Duration [ Time Frame: 12 months ]
   Using actigraph and a structured questionaire on all children at baseline and at end of study measure the extent to which the intervention affects sleep.

Other Outcome Measures:

1. Extended Followup: Neurodevelopment [ Time Frame: 3 years ]
   We will follow the cohort beyond the planned (and funded) project period and measure neurodevelopment using appropriate tests such as the Wechsler tests
2. Surrogate Markers for Neurodevelopment [ Time Frame: 2 years ]
   If funding allows, measure other markers related to neurodevelopment such as Brain Derived Neurotrophic Factor

Eligibility Criteria

• Ages Eligible for Study: 6 Months to 11 Months (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Age 6 to 11 months
• Stunted
• Availability of informed verbal consent
• Plan to reside in the area for the next 12 months

Exclusion Criteria:

• Severe systemic illness requiring hospitalization
• Severe malnutrition, i.e. weight for height < -3 z of the WHO standard for this age group. For ethical reasons these children require micronutrient supplementation and adequate medical care.
• Lack of consent
• Taking B vitamin supplements that include vitamin B12.
• Severe anemia (Hb < 7 g/dL). This would be a temporary exclusion and the children will be enrolled if they are successfully treated.
• Ongoing acute infection with fever or infection that requires medical treatment. This would be a temporary exclusion and the children will be enrolled after recovery.

Contacts and Locations

Locations

Nepal

Siddhi Memorial Hospital (SMH),Bhelukhel, Bhimsensthan

Bhaktapur, Nepal, P.O.Box 40

Sponsors and Collaborators

Centre For International Health

Tribhuvan University, Nepal

NORCE Norwegian Research Centre AS

Investigators

• Principal Investigator: Prakash S Shrestha, MD; Tribhuvan University, Nepal
• Principal Investigator: Tor A Strand, MD/PhD; Innlandet Hospital Trust / University of Bergen

  Study Documents (Full-Text)

Documents provided by Centre For International Health:

Study Protocol  [PDF] April 2, 2020

Statistical Analysis Plan  [PDF] October 15, 2019

More Information

Additional Information:

Link to the founding source. 

Publications:

Taneja S, Strand TA, Kumar T, Mahesh M, Mohan S, Manger MS, Refsum H, Yajnik CS, Bhandari N. Folic acid and vitamin B-12 supplementation and common infections in 6-30-mo-old children in India: a randomized placebo-controlled trial. Am J Clin Nutr. 2013 Sep;98(3):731-7. doi: 10.3945/ajcn.113.059592. Epub 2013 Jul 31.

Strand TA, Taneja S, Ueland PM, Refsum H, Bahl R, Schneede J, Sommerfelt H, Bhandari N. Cobalamin and folate status predicts mental development scores in North Indian children 12-18 mo of age. Am J Clin Nutr. 2013 Feb;97(2):310-7. doi: 10.3945/ajcn.111.032268. Epub 2013 Jan 2.

Black MM. Effects of vitamin B12 and folate deficiency on brain development in children. Food Nutr Bull. 2008 Jun;29(2 Suppl):S126-31. Review.

Black MM. Micronutrient deficiencies and cognitive functioning. J Nutr. 2003 Nov;133(11 Suppl 2):3927S-3931S. doi: 10.1093/jn/133.11.3927S. Review.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Hysing M, Strand TA, Chandyo RK, Ulak M, Ranjitkar S, Schwinger C, Shrestha M, Kvestad I. The effect of vitamin B12-supplementation on actigraphy measured sleep pattern; a randomized control trial. Clin Nutr. 2022 Feb;41(2):307-312. doi: 10.1016/j.clnu.2021.11.040. Epub 2021 Dec 6.

Strand TA, Ulak M, Hysing M, Ranjitkar S, Kvestad I, Shrestha M, Ueland PM, McCann A, Shrestha PS, Shrestha LS, Chandyo RK. Effects of vitamin B12 supplementation on neurodevelopment and growth in Nepalese Infants: A randomized controlled trial. PLoS Med. 2020 Dec 1;17(12):e1003430. doi: 10.1371/journal.pmed.1003430. eCollection 2020 Dec.

Strand TA, Ulak M, Chandyo RK, Kvestad I, Hysing M, Shrestha M, Basnet S, Ranjitkar S, Shrestha L, Shrestha PS. The effect of vitamin B(12) supplementation in Nepalese infants on growth and development: study protocol for a randomized controlled trial. Trials. 2017 Apr 21;18(1):187. doi: 10.1186/s13063-017-1937-0.

• Responsible Party: Centre For International Health
• ClinicalTrials.gov Identifier: NCT02272842
• Other Study ID Numbers: 808734; U1111-1161-5187 ( Other Identifier: WHO )
• First Posted: October 23, 2014
• Results First Posted: May 25, 2021
• Last Update Posted: May 25, 2021
• Last Verified: May 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: Data available on request. In order to meet ethical requirements for the use of confidential patient data, requests must be approved by the Nepal Health Research Council (NHRC) and the Regional Committee for Medical and Health Research Ethics in Norway. Requests for data should be sent to the authors, by contacting NHRC (http://nhrc.gov.np), or by contacting the Department of Global Health and Primary Care at the University of Bergen (post@igs.uib.no).
• Supporting Materials: Study Protocol; Statistical Analysis Plan (SAP); Informed Consent Form (ICF); Clinical Study Report (CSR)
• Time Frame: Upon publication of the main outcomes.
• Access Criteria: The protocols and the plan of analyses will be available with the main publication. IPD will be available following an application process which involves the ethical committees in Norway and Nepal

Keywords provided by Centre For International Health:

Nepal; Cobalamin; Neurodevelopment; Stunting; Growth

Additional relevant MeSH terms:

Malnutrition; Avitaminosis; Nutrition Disorders; Deficiency Diseases; Vitamin B 12; Hydroxocobalamin; Vitamins; Micronutrients; Physiological Effects of Drugs; Vitamin B Complex; Hematinics